Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | P4HB | P07237 | 5/20 | 0.61 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15807423 | 0.92 | ABCG2 (0.68) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL9520743 | 0.90 | MAPT (0.73) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL9520750 | 0.90 | MAPT (0.73) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL27903979 | 0.89 | F3 (0.77) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14318118 | 0.89 | F3 (0.77) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14306001 | 0.88 | ABCG2 (0.82) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL996620 | 0.86 | ABCG2 (0.93) | ABCG2MAPTALDH1A1LMNAP4HB | |
| SCHEMBL996618 | 0.86 | ABCG2 (0.93) | ABCG2MAPTALDH1A1LMNAP4HB | |
| SCHEMBL14306013 | 0.85 | ABCG2 (0.79) | ABCG2MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14317391 | 0.85 | P4HB (0.83) | ABCG2P4HBCYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10737995-B2 | Nuclear receptor modulators and their use for the treatment and prevention of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190047932-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-02-14 | — | — | US | disclosed |
| EP-3333153-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20140171503-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012174436-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047932-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | AR, NCOA1, NR5A1 | ABCG2 742/4885MAPT 4183/4885ALDH1A1 902/4885 |
| US-10737995-B2 | Nuclear receptor modulators and their use for the treatment and prevention of cancer | AR, NCOA1, NR5A1 | ABCG2 742/4885MAPT 4183/4885ALDH1A1 902/4885 |
| US-20140171503-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | AR, NCOA1, NR5A1 | ABCG2 742/4885MAPT 4183/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.